Opendata, web and dolomites

MeningoSpeed SIGNED

A unique cost-effective and point of care (PoC) kit for the non-invasive rapid in vitro diagnosis of meningococcal disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MeningoSpeed project word cloud

Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.

capability    people    valued    net    source    acute    meningococcal    disruptive    cagr    finalize    financial    accurate    meningitidis    accumulated    ca    epidemic    burden    agglutination    33    2022    tests    15    secure    first    invasive    abcxwy    technological    launch    infectious    vast    faster    limited    biospeedia    neisseria    savings    immunochromatographic    min    despite    diseases    commercial    france    45    nm    lethality    pasteur    care    gt    permanent    meningospeed    latex    point    off    least    tools    costly    25    fashion    tool    disease    worldwide    plan    patients    cheaper    10    projected    93    treatment    children    3h    physicians    public    hospital    performance    alternatives    market    health    opportunity    vitro    caused    feasibility    lt    deaths    business    successful    specificity    annually    solution    purchasers    sensitivity    gold    monitoring    profit    nanoparticle    company    societal    spin    young    profitable    vs    diagnosis    healthcare    md    added    competitive    direct    accuracy    68    sequelae    diagnostic    core    lack    reducing    million    mainly    six    rapid    pcr    unmet    2026    serogroups    demonstrated   

Project "MeningoSpeed" data sheet

The following table provides information about the project.

Coordinator
BIOSPEEDIA 

Organization address
address: INSTITUT PASTEUR - 25 RUE DU DOCTEUR ROUX
city: PARIS
postcode: 75724
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.biospeedia.com/index.php/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOSPEEDIA FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More